Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY010616
- Development stage
- Phase 2
- Lead developer
- Luye Pharma
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LY010616 (also known as LY01616) is an investigational liposomal formulation co-encapsulating irinotecan and floxuridine, developed by Luye Pharma Group. Irinotecan is a topoisomerase I inhibitor, while floxuridine is a fluoropyrimidine antimetabolite. By co-encapsulating these two synergistic chemotherapy agents in a liposome delivery system, the drug aims to optimize the drug ratio and delivery to tumor tissues, potentially enhancing efficacy and reducing systemic toxicity compared to conventional administration. It is currently being evaluated in Phase I/II clinical trials for the treatment of advanced solid tumors.
- Other names
- Irinotecan Hydrochloride and Floxuridine Liposome InjectionIrinotecan and Floxuridine Liposome
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on LY010616.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY010616.